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COMPARISON OF THE EFFICACY OF
CARBAMAZEPINE, HALOPERIDOL AND
VALPROIC ACID IN THE TREATMENT OF
CHILDREN WITH SYDENHAM´S CHOREA
Clinical follow-up of 18 patients
Joaquín Peña1, Eduardo Mora2, José Cardozo3, Omaira Molina3, Cecilia Montiel1
ABSTRACT - In order to compare and contrast the efficacy of haloperidol, carbamazepine, and valproic acid in
the treatment of Sydenham´s chorea a prospective study including 18 cases of this disorder was undertaken.
Age of patients ranged from 7 to 15 years. Ten children were female and 8 were male. All but one had
generalized, either symmetric or asymmetric chorea. The patients were divided in three equal groups, and
were given a standardized dose of each of the drugs built-up over a week. Following therapy, the six children
receiving valproic acid showed remarkable improvement, without side effects. Five patients receiving
carbamazepine showed improvement without side effects. Only three of the patients that received haloperidol
improved. In the 4 cases that did not show clinical improvement after one week of treatment, therapy with
valproic acid led to disappearance of the symptoms in a lapse that ranged from 4 to 7 days. Recurrence
related to discontinuation of treatment was observed in two patients. In view of the present results we
recommend valproic acid as the first choice drug to treat Sydenham chorea.
KEY WORDS: Sydenham´s chorea, carbamazepine, haloperidol, valproic acid.

Comparación de la eficacia de carbamazepina, haloperidol y acido valproico en el tratamiento de niños
con corea de Sydenham: seguimiento clínico de 18 pacientes
RESUMEN - A fin de comparar y contrastar la eficacia de haloperidol, carbamazepina y ácido valproico en el
tratamiento de la corea de Sydenham, se realizó un estudio prospectivo que incluyó 18 casos de esta patología.
La edad de los pacientes varió de 7 a 15 años. Diez de los niños eran varones y el resto hembras. A excepción
de uno de ellos, todos tenían corea generalizada, simétrica ó asimétrica. Los pacientes fueron divididos en tres
grupos iguales, a cada uno de los cuales se le administró una dosis estandarizada de los medicamentos
mencionados durante una semana. Luego del tratamiento, los seis pacientes que recibieron ácido valproico
mostraron mejoría notable sin efectos colaterales. Cinco de los seis pacientes que recibieron carbamazepina
exhibieron mejoría sin efectos colaterales. Solo tres de los pacientes que recibieron haloperidol mejoraron. En
los cuatro casos que luego de recibir estas dos últimas drogas sin experimentar mejoría clínica luego de una
semana, se instaló terapia con ácido valproico, lo que llevó a desaparición de la sintomatología en un lapso de
4 a 7 días. Se observó recaída relacionada con tratamiento discontinuado en dos de los pacientes. A la vista de
nuestros resultados, recomendamos el ácido valproico como droga de primera elección en el tratamiento de
la corea de Sydenham.
PALABRAS CLAVE: corea de Sydenham, acido valproico, carbamazepina, haloperidol.

Sydenham´s chorea (SC) is the most prevalent
form of acquired chorea, and it constitutes a major
manifestation of rheumatic fever1. Thomas Sydenham
originally described this ailment in 1866. Involuntary
movements, lack of motor coordination and emo-

tional instability characterize it2. In a remarkable
number of cases the disease is self-limited, hence
bed rest in a quiet environment, and stress avoidance may suffice. However, in patients with moderate or severe movement disorders, the accompany-
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ing anxiety, obsessive-compulsive signs, and other
associated psychological dysfunction may prevent
daily activities and brings into consideration therapy
with specific medication, in spite of the fact that
most of such drugs have side effects that limit their
use. An impressive list of therapeutic options has
been used to treat this disorder: ketogenic diet, amphetamines, steroids, haloperidol (HP), valproic acid
(VPA), carbamazepine (CBZ), reserpine, chlorpromazine, and phenobarbital3-5. Many reports confirm
the efficacy of HP, CBZ and VPA in uncontrolled studies6-11, and only a few controlled investigations compare the efficacy and side effects of currently used
medications. A recent prospective study that included 10 children with chorea suggests that CBZ may
prove useful as the drug of choice for the treatment
of rheumatic chorea12. In another recent trial that
compared HP and sodium valproate in a series of 24
patients, the percentage of individuals that responded to treatment was significantly higher in the HP
group13.
The purpose of the present investigation is to
compare and contrast the efficacy of HP, CBZ, and
VPA in the treatment of SC in a series of 18 patients
through the analysis of clinical and laboratory findings, clinical course, and side effects related to these
drugs.
METHOD
The study group included 32 patients with SC that were
referred to the Pediatric Neurology department of the
University Hospital of Maracaibo, Venezuela during the
period January 1st. 1995 – December 31, 1999. Patient
selection was based on the following criteria: a) clinical
findings consistent with the diagnosis of SC, such as abnormal movements and emotional liability; b) clinical
course of less than 4 weeks; c) no previous history of choreic episodes; d) no previous history of treatment with other
drugs. Fourteen patients were excluded from the trial because they failed to meet the required selection parameters. The symptoms recorded in the remaining 18 cases
were classified as mild, moderate or severe according to
the criteria established by Aron et al.14. The study protocol included a complete clinical history with detailed information regarding family history, form of presentation,
signs and symptoms, clinical course, duration, associated
manifestations. Laboratory tests included hemogram, liver
function, antistreptolysin O and streptozyme titers, erythrocyte sedimentation, reactive C-protein, LE cells, antinuclear antibodies, complement, anticardiolipin antibodies; electrocardiography, electroencephalography and
neuroimaging. The type of treatment was decided randomly according to the order of admission to the hospital. Six patients were treated with haloperidol at a dose of
3 mg/day, b. i. d.; 6 patients were assigned to the valproic
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acid group (20 mg/kg/day, b.i.d.), and the remaining 6
patients were given carbamazepine (15-20 mg/kg/day,
b.i.d.).
The response to treatment was assessed by the clinical course and daily neurological evaluation. Each drug
was maintained for at least a week, and the efficacy or
failure of the treatment with each of the drugs was determined by the disappearance of the symptomatology as
assessed by the visual scale. In case of failed response, the
medication of first choice was discontinued and treatment
with a different drug was installed. No treatment withdrawal occurred during the study period.
The study was authorized to be carried out by the Ethics Committee of the University Hospital.

RESULTS
Clinical and ancillary findings
Ten females and eight males, aged 7-15 years
were included in the study. None of the patients had
family history of SC. Abnormal movements were
generalized, either symmetric or asymmetric in 17
cases and unilateral in one case. The distribution of
the cases according to the different abnormal movements observed upon admission is displayed in Table
1. As shown in Table 2, in addition to the choreic
movements other clinical manifestations that were
readily evident, included emotional instability, gait

Table 1. Type of abnormal movements in 18 cases of Sydenham´s
chorea studied.
Type of dyskinesia

n

%

Generalized, asymmetric

10

55.5

Generalized, symmetric

5

27.7

Unilateral

1

5.5

Choreiform status

1

5.5

Chorea mollis

1

5.5

Table 2. Associated neurological manifestations in 18 patients
with Sydenham´s chorea studied.
Neurological symptom

n

%

Behavior alterations

13

72.2

Gait disturbance

10

55.5

Motor agitation

10

55.5

Reflex abnormalities

8

44.4

Dysarthria

7

38.8

Weakness

3

16.6
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disturbances, motor agitation, abnormal reflexes,
dysarthria, and generalized weakness. Three patients
developed mitral valve insufficiency. Sptreptozyme
values were increased in 10 patients (55.5 %). Increased antistreptolysin -O (ASO) titers were found in 7
patients (38.8%). Both increased erythrocyte sedimentation rate and positive reactive C-protein were
evident in 3 cases (16.6%) LE cells, antinuclear and
anticardiolipin antibodies were negative in all cases.
EEG was abnormal in 7 patients (38.8%) It displayed
slow and intermittent delta waves in the parietooccipital region after eye closure. This was observed
during the first two weeks of the clinical course, and
disappeared 4-8 weeks later. Neuroimaging revealed
no abnormalities.

Response to treatment
Complete recovery was observed in five of the
patients treated with VPA following 5 days of treatment, whereas moderate improvement was recorded
in the remaining case. Full recovery was achieved in
five of the six patients treated with CBZ, three of these
cases recovered after 5 days of treatment, whereas
the other two required of treatment during 7 days
before disappearance of symptoms was observed.
The remaining case failed to improve. No side effects
due to VPA o CBZ were documented. Three of the
six patients treated with HP showed improvement
following 5 days of treatment, two of these had
treatment related side effects: one patient displayed
excessive somnolence, whereas the other one had a
dystonic reaction. Medication administration was
interrupted in the four patients that failed to improve, and treatment with VPA was started. One week
later these patients were symptom-free.
The duration of treatment varied from 1 to 14
months. Follow-up ranged from 10 months to 3 years.
Recurrence was documented in two patients at 3
and 10 months of therapy, respectively; one of these
patients had received CBZ, and the other HP. Reinstallation of therapy with VPA was followed by improvement. This drug was administered during 6 and
10 months, respectively.
DISCUSSION
SC is a movement disorder that affects patients
aged 5 to 15 years, with a peak incidence at 8 years,
and a 2:1 female predominance15. The neurological
manifestations are usually preceded by emotional
instability, low scholar achievement and motor clumsiness. The involuntary movements that characterize this ailment are jerky, uncoordinated, brief, generalized though predominantly asymmetric, and in-

volve the hands, arms, and to a lesser degree the neck,
face and tongue. These motor alterations appear
when the patient is at rest, and may cease during sleep.
A genetic predisposition to develop CS has been
suggested14-16.
As stated above, in addition to the movement disorders these patients present with assorted behavioral problems that include emotional instability,
mood changes and depression. Thus, the condition
may be misdiagnosed as an ailment of psychological origin.
Several studies have stressed an antecedent of
streptococcal infection in up to 60% of the cases17.
In the present series we could not demonstrate a history of streptococcal infection, or physical signs suggestive of such. Conversely, we found significant alterations in serologic tests, especially the ASO test
that was elevated in 38.8% of the cases. Previous
studies have signaled that up to 25% of cases of SC
reveal normal ASO values18,19. This contrasts with acute rheumatic fever, which consistently displays increased ASO titers. The increment observed in the
former usually appears early during the course of
the infection and diminishes rapidly before the clinical signs of chorea develop. Comparatively, the streptozyme test appears to be more sensible than other
bacterial antigens. This test defines antibodies to five
streptococcal exo-enzymes, including streptolysineO, and its titers remain elevated for several weeks.
Other studies have signaled the value of anti-DNAase
B and anti DNAase test in the diagnosis of SC, with
increased titers in 63% of the patients up to 6 months
after the onset of symptoms20. The variability in the
results of the serologic tests may occur as a consequence of differences among the streptococcal
strains, or they may be secondary to the presence of
other precipitants21,22. The diagnosis of SC is based
on the clinical examination, and the elimination of
other causes of chorea. Most of changes observed
in the EEG are transient, and they rapidly disappear
in a matter of weeks. Neuroimaging is usually unremarkable22-25.
The pathogenesis of SC is related to a biochemical dysfunction of the corpus striatum in response
to a streptococcal infection26-28. The abnormal balance between the dopaminergic and cholinergic systems that determines dopaminergic hyperactivity has
been pointed out as the main mechanism underlying SC. Thus, therapy is aimed at re-establishing that
balance8,9.
The clinical course of patients with SC treated with
several drugs follows a path that leads to the pro-
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gressive disappearance of the symptoms. Sedatives,
dopaminergic receptor antagonists, and other drugs
reduce the time of convalescence of the patients that
harbor this disorder, with varying degrees of success. HP, a dopamine receptor blocker, has been used
to treat SC, although this drug is frequently associated with side effects such as parkinsonism and dystonia29. Cuellar et al.13 reported the successful use of
HP as compared to VP in a group of 24 patients with
SC. A dose of 0.05-0.1 mg/kg/day, b.i.d. was administered. The onset of symptoms preceded the hospital admission ranging from 1 to 30 days in 15 patients, and in more than 30 days in 9 cases. Authors
that have used VPA or sodium valproate in SC reported similar results as those obtained with HP, with
less adverse effects, notwithstandingly5,11,30. The
mechanism through which VP improves chorea is
related to an increase in the glutamic acid decarboxylase activity and the inhibition of GABA transaminase, which determines an elevation of brain
GABA levels5,30.
Other authors have recently reported the beneficial effect of CBZ in patients with SC. It is not well
known how CBZ works in CS. A possible blockade of
the dopaminergic postsynaptic receptors and stimulation of the cholinergic pathways has been hypothesized8,9.
The three groups of patients that constituted the
present series displayed clinical symptoms of 2–3
weeks duration, without evidence of spontaneous
recovery before the beginning of treatment. The
number of patients that responded to treatment at
the end of the first week was discreetly higher in the
group that received VPA. In addition, the time to
improvement was significantly shorter in this group
as compared to both the HP and CBZ groups.
Our results indicate that VPA is both effective and
safe because of its low effective dose, and rapid response. Nevertheless, we are aware that the disparity among the different studies that have been performed to test the efficacy of a particular drug is
related to several issues. Thus, other multicentric and
comparative studies involving more patients are
mandatory in order to answer the question of which
drug is best for each particular child affected by SC.
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